Galangin as a Therapeutic Agent for Wound Healing: Pharmacology, Challenges, and Advanced Delivery Systems

Abstract

Galangin (3,5,7-trihydroxyflavone) is a naturally occurring flavonoid predominant in plants such as Alpinia officinarum (lesser galangal), galangal rhizomes and propolis. Its broad pharmacological profile includes antioxidant, anti-inflammatory, antimicrobial, anti-fibrotic, and cell-modulatory effects. Although most research has focused on cancer, cardiovascular, and fibrotic diseases, emerging evidence suggests potential roles for galangin in wound healing and dermal repair processes. However, critical challenges such as poor solubility, low bioavailability, rapid metabolism, and limited clinical translation have impeded its therapeutic development. Advanced delivery systems — including hydrogels, nanoparticles, and biopolymer carriers — provide promising strategies to overcome these limitations. This review synthesizes the current evidence on galangin’s pharmacology in wound healing, discusses mechanistic pathways, highlights challenges for clinical application, and explores advanced delivery platforms designed to enhance its therapeutic potential.Wound healing is a highly coordinated biological process involving inflammation, cell migration, angiogenesis, extracellular matrix deposition, and tissue remodeling. Impairment in any of these phases can lead to chronic, non-healing wounds, representing a significant clinical challenge. Galangin (3,5,7-trihydroxyflavone), a naturally occurring flavonoid found in Alpinia officinarum, propolis, and related plant sources, has attracted increasing attention due to its diverse pharmacological activities. Galangin exhibits potent anti-inflammatory, antioxidant, antimicrobial, and anti-fibrotic properties, which are highly relevant to key stages of wound repair. Experimental studies suggest that galangin can modulate inflammatory mediators, regulate fibroblast migration and proliferation, suppress excessive collagen deposition through the TGF-?/Smad signaling pathway, and reduce oxidative stress, thereby promoting more effective wound healing. Despite these promising effects, the therapeutic application of galangin is limited by poor aqueous solubility, low bioavailability, rapid metabolism, and insufficient in vivo and clinical evidence.

Keywords

Galangin; Wound healing; Flavonoids; Anti-inflammatory activity; Antioxidant activity; Fibroblast migration; TGF-?/Smad signaling; Chronic wounds; Drug delivery systems; Hydrogels; Nanoparticles; Controlled drug delivery

Introduction

To overcome these challenges, researchers are utilizing nanotechnology and biomaterials to enhance galangin's delivery to the wound site.

Nano-Carrier Systems

• Liposomes & Niosomes: Encapsulating galangin in lipid bilayers improves its solubility and allows for a controlled, sustained release. These vesicles can fuse with skin cell membranes to enhance deep-tissue penetration.
• Polymeric Nanoparticles (PLGA/ Chitosan): Biodegradable polymers protect galangin from enzymatic degradation in the wound bed. Chitosan-based particles also provide inherent antimicrobial synergy.
• Gold Nanoparticles (AuNPs): Galangin-conjugated AuNPs have shown promise in modulating angiogenesis and cell migration, potentially speeding up the proliferative phase of healing.

Scaffolds and Hydrogels

• Electrospun Nanofibers: Mimicking the natural ECM, these fibers can be loaded with galangin to provide a high surface-area-to-volume ratio for drug release while providing a physical scaffold for cell growth.
• Smart Hydrogels: These "intelligent" dressings can respond to the wound environment (e.g., pH or temperature changes) to trigger the release of galangin exactly when inflammation or infection levels rise.

Pharmacology: How Galangin Heals

Galangin acts as a "biological orchestrator" that accelerates the body's natural repair mechanisms through several distinct pathways:

• Anti-inflammatory Control: It suppresses the NF-$\kappa$B and MAPK signaling pathways. By doing so, it reduces the release of pro-inflammatory cytokines such as TNF-$\alpha$ and IL-6, preventing wounds from becoming "stuck" in a chronic inflammatory state.
• Oxidative Stress Reduction: It activates the Nrf2/ARE pathway, which triggers the production of internal antioxidants like Superoxide Dismutase (SOD) and Catalase. This protects new cells from being destroyed by Reactive Oxygen Species (ROS).
• Promotion of Angiogenesis: Galangin has been shown to upregulate VEGF (Vascular Endothelial Growth Factor), which stimulates the formation of new blood vessels, ensuring the healing tissue receives oxygen and nutrients.
• Extracellular Matrix (ECM) Stability: It regulates Matrix Metalloproteinases (MMPs), ensuring that collagen is deposited in an organized fashion rather than being prematurely broken down.

Clinical Challenges: The Solubility Barrier

Despite its high efficacy in laboratory tests, Galangin faces three primary "bottlenecks" that hinder its use as a standard medical treatment:

1. Poor Solubility: It is highly hydrophobic (water-hating), meaning it doesn't dissolve well in standard medical gels or blood, leading to poor absorption.
2. Low Bioavailability: When applied to the skin, very little of the drug actually reaches the deep dermal layers where the most critical healing occurs.
3. Environmental Sensitivity: It can degrade quickly when exposed to light or the varying pH levels of a wound environment.

3. Advanced Delivery Systems

To solve these problems, researchers are using Nanotechnology to "wrap" Galangin in protective carriers:

Delivery System	Mechanism of Action	Benefit
Nanofibrous Scaffolds	Mimics the skin's physical structure.	Provides a "home" for cells to grow while releasing drug slowly.
Liposomes/ Niosomes	Fatty "bubbles" that carry the drug.	Penetrates the skin's lipid barrier more effectively.
Hydrogel Nanocomposites	Smart gels that respond to pH or heat.	Releases Galangin only when the wound is inflamed or infected.
Gold Nanoparticles	Metallic carriers conjugated with Galangin.	Enhances antimicrobial action and improves targeted delivery.

Pharmacological Mechanisms in Wound Healing

Galangin accelerates tissue repair by orchestrating cellular responses across the four stages of wound healing (Hemostasis, Inflammation, Proliferation, and Remodeling).

A. Anti-inflammatory & Immunomodulatory Activity¹

Chronic wounds often stall in the inflammatory phase.² Galangin effectively "unlocks" this stage by:

• NF-$\kappa$B Inhibition: It prevents the phosphorylation of I$\kappa$B$\alpha$, thereby blocking the NF-$\kappa$B pathway and reducing the production of pro-inflammatory cytokines like TNF-$\alpha$, IL-6, and IL-1$\beta$.
• MAPK Pathway Regulation: By modulating Mitogen-Activated Protein Kinase (MAPK) signaling, it controls the recruitment of neutrophils and macrophages to the wound site.

B. Oxidative Stress Mitigation

Excessive ROS (Reactive Oxygen Species) destroys healthy tissue. Galangin acts as a "bio-shield" through:

• Nrf2/HO-1 Activation: It stimulates the Nrf2 pathway, leading to increased production of antioxidant enzymes like Superoxide Dismutase (SOD) and Catalase (CAT).
• Lipid Peroxidation Reduction: It decreases levels of Malondialdehyde (MDA), preserving the integrity of cell membranes in fibroblasts and keratinocytes.

C. Angiogenesis and Tissue Regeneration

• Growth Factor Modulation: Galangin has been shown to upregulate VEGF (Vascular Endothelial Growth Factor) and TGF-$\beta$1, promoting the formation of new capillary networks essential for oxygenating the wound bed.
• Stem Cell Activation: Recent 2024–2025 studies suggest Galangin can activate Tendon-Derived Stem Cells (TDSCs) and mesenchymal stem cells via JAK2/STAT3 signaling, facilitating deeper tissue repair.

D. Remodeling & Anti-Scarring

• MMP Regulation: It inhibits Matrix Metalloproteinases (MMP-2 and MMP-9), ensuring that the extracellular matrix (ECM) is built effectively without excessive degradation.
• Hypertrophic Scar Prevention: By modulating the TGF-⁶$\beta$/Smad pathway, it balances collagen types I and III, reducing the risk of abnormal, raised scarring.

Key Challenges in Therapeutic Application

Despite its benefits, Galangin’s "natural" form presents significant hurdles for clinical use:

Barrier	Impact on Wound Healing
Hydrophobicity	Virtually insoluble in water; difficult to formulate into standard gels.
Poor Bioavailability	Rapidly metabolized and poorly absorbed through the thick skin barrier.
Stability Issues	Highly sensitive to light and pH; degrades quickly in the alkaline environment of chronic wounds.
Washout Effect	Free Galangin is quickly diluted or removed by wound exudate (fluid).

3. Advanced Delivery Systems (The "Solution")

To bridge the gap between lab and clinic, researchers are using Nano-Medicine to deliver Galangin effectively:

• Nanofibrous Scaffolds: Electrospun fibers (often made of Chitosan or PLGA) mimic the skin's natural structure. They act as a "second skin" that releases Galangin slowly while allowing the wound to "breathe."
• Nanostructured Lipid Carriers (NLCs): These lipid-based "bubbles" encapsulate Galangin, allowing it to penetrate the fatty layers of the skin and reach the deep dermis where regeneration occurs.
• Stimuli-Responsive Hydrogels: "Smart" hydrogels that release Galangin only when they sense a specific trigger, such as a change in wound temperature or the presence of bacterial enzymes (pH-triggered release).
• Metallic Nanoparticles: Conjugating Galangin with Gold Nanoparticles (AuNPs) has been shown to enhance its antimicrobial and anti-tumor properties, providing a dual-action dressing for infected wounds or post-surgical recovery.

CONCLUSION

In summary, the transition of Galangin ($3,5,7$-trihydroxyflavone) from a traditional herbal constituent to a sophisticated therapeutic agent represents a significant advancement in the field of regenerative medicine. This review has delineated the multifaceted role of Galangin in wound healing, underscoring its ability to modulate the complex biochemical environment of injured tissue through a synergy of pharmacological actions, while also addressing the technological hurdles that have historically limited its clinical utility.

Pharmacological Integration

The pharmacological profile of Galangin is remarkably comprehensive, addressing the primary barriers to successful tissue repair. Its ability to act as a potent anti-inflammatory agent via the inhibition of the NF-¹$\kappa$B and MAPK pathways is critical in preventing the chronicity of wounds.² Furthermore, its role in oxidative stress management through the Nrf2/HO-1 axis provides a "bio-shield" for migrating fibroblasts and keratinocytes. Perhaps most importantly, Galangin’s influence on angiogenesis and the regulation of Matrix Metalloproteinases (MMPs) ensures that the remodeling phase results in functional tissue rather than pathological fibrosis. This multi-target approach makes it superior to single-target synthetic drugs that often fail to address the holistic complexity of the wound bed.

Addressing the Bioavailability Gap

Despite these benefits, the "Galangin Paradox"—the gap between its high in vitro efficacy and poor in vivo performance—remains the central challenge. The molecule’s inherent hydrophobicity, low aqueous solubility, and susceptibility to rapid metabolic degradation necessitate a departure from conventional topical formulations. Simple ointments and creams are insufficient to maintain the sustained therapeutic concentrations required for deep-tissue repair, particularly in the presence of wound exudates that can easily wash away free active compounds.

The Future of Advanced Delivery

The emergence of advanced delivery systems marks the "enabling" phase of Galangin research. The integration of nanotechnology, including liposomes, polymeric nanoparticles, and electrospun scaffolds, has successfully transformed Galangin into a viable clinical candidate. These systems do more than just deliver the drug; they protect the molecule from environmental degradation, enhance its penetration through the skin barrier, and provide a sustained-release profile that reduces the need for frequent dressing changes. The development of "smart" hydrogels, which can release Galangin in response to specific wound triggers such as pH shifts or bacterial enzymes, represents the next frontier in personalized wound management.

Final Verdict

In conclusion, Galangin stands as a promising "all-in-one" natural therapeutic for the treatment of acute and chronic wounds, including diabetic ulcers and severe burns. While the laboratory evidence is robust, the future of Galangin-based therapy depends on the successful translation of these advanced delivery platforms into human clinical trials. By bridging the gap between ancient pharmacology and modern material science, Galangin-loaded biomaterials are poised to become a cornerstone in the next generation of wound-care products, offering a cost-effective, natural, and highly efficient solution for global healthcare challenges.

REFERENCES

1. Lynch SE, Trippel SB, Finkelman RD, Hernandez RA, Kiritsy CP, Antoniades HNJWR, et al. The combination of platelet? derived growth factor? BB and insulin? like growth factor? I stimulates bone repair in adult Yucatan miniature pigs. 1994;2(3):182-90.
2. Cowan JB, Bedi A, Carpenter JE, Robbins CB, Gagnier JJ, Miller BSJJoS, et al. Evaluation of American Academy of Orthopaedic Surgeons Appropriate Use Criteria for the management of fullthickness rotator cuff tears. 2016;25(7):1100-6.
3. Gurtner GC, Werner S, Barrandon Y, Longaker MTJN. Wound repair and regeneration. 2008;453(7193):314-21.
4. Barrientos S, Brem H, Stojadinovic O, Tomic? Canic MJWR, Regeneration. Clinical application of growth factors and cytokines in wound healing. 2014;22(5):569-78.
5. Bowler P, Duerden B, Armstrong DGJCmr. Wound microbiology and associated approaches to wound management. 2001;14(2):244-69.
6. Eming SA, Krieg T, Davidson JMJJoID. Inflammation in wound repair: molecular and cellular mechanisms. 2007;127(3):514-25.
7. Veves AJDC. Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. 2001;24:290-5
8. Rees PA, Greaves NS, Baguneid M, Bayat AJAiwc. Chemokines in wound healing and as potential therapeutic targets for reducing cutaneous scarring. 2015;4(11):687-703.
9. Zhang F, Xu C-L, Liu C-MJDD, Development, Therapy. Drug delivery strategies to enhance the permeability of the blood–brain barrier for treatment of glioma. 2015:2089-100.
10. Schultz GS, Davidson JM, Kirsner RS, Bornstein P, Herman IMJWR, Regeneration. Dynamic reciprocity in the wound microenvironment. 2011;19(2):134-48.
11. Li J, Mooney DJJNRM. Designing hydrogels for controlled drug delivery. 2016;1(12):1-17.
12. Giovagnoli S, Mancuso F, Vannini S, Calvitti M, Piroddi M, Pietrella D, et al. Microparticle-loaded neonatal porcine Sertoli cells for cell-based therapeutic and drug delivery system. 2014;192:249-61.
13. Larrañeta E, Lutton RE, Woolfson AD, Donnelly RFJMS, Reports ER Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development. 2016;104:1-32.
14. Sill TJ, Von Recum HAJB. Electrospinning: applications in drug delivery and tissue engineering. 2008;29(13):1989-2006.
15. Murphy SV, Atala AJNb. 3D bioprinting of tissues and organs. 2014;32(8):773-85.
16. Bowler P, Jones S, Walker M, Parsons DJJoBC, Rehabilitation. Microbicidal properties of a silver-containing Hydrofiber® dressing against a variety of burn wound pathogens. 2004;25(2):192-6.
17. Thomas S, McCubbin PJJowc. A comparison of the antimicrobial effects of four silver-containing dressings on three organisms. 2003;12(3):101-7.
18. Swanson T, Angel D, Sussman G, Cooper R, Haesler E, Ousey K, et al. Wound infection in clinical practice: principles of best practice. 2016.
19. Burke JF, Yannas IV, Quinby Jr WC, Bondoc CC, Jung WKJAos. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. 1981;194(4):413.
20. Refaat H, Mady FM, Sarhan HA, Rateb HS, Alaaeldin EJIjop. Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19. 2021;592:120028.
21. Glover RL, Nyanganyura D, Mufamadi MS, Mulaudzi RB. Green Synthesis in Nanomedicine and Human Health: CRC Press; 2021.
22. Almal SH, Padh HJIJoPS. Variation in Copy Number of MTUS1 Gene among Healthy Individuals and Cancer Patients from Gujarat. 2017;79(2).